Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly

Objectif

The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share validated methods to evaluate post marketing vaccine performances. The objectives are to identify, pilot test, and disseminate in EU the best study designs to measure, on a real time basis, VE (direct effect) and the VI of vaccination programmes (indirect and overall effect) against laboratory confirmed cases of influenza (types/subtypes) and pneumococcal disease (serotypes), and clinical outcomes. Cost effectiveness analysis will be conducted.

Results will allow to understand factors affecting specific VE, the duration of protection of influenza and pneumococcal vaccines, the interaction between vaccines, the role of repeated vaccinations, the occurrence of serotype replacement (pneumococcus); identify vaccine types and brands with low VE; guide the decision of the WHO committees on vaccine strain selection (influenza); provide robust benefit indicators (VE and VI) and cost benefit and effectiveness results; guide vaccination strategies (schedules, doses, boosters). This EU member state collaboration will respond to questions that require studies based on large sample sizes and sharing of expertise that cannot be achieved by one country alone. It will allow the best methods to be used and results to benefit to all EU countries whatever their current public health achievements. Results will be shared with international partners.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Programme(s)

Thème(s)

Régime de financement

RIA -

Coordinateur

EPICONCEPT
Contribution nette de l'UE
€ 1 550 373,38
Adresse
RUE TITON 27
75011 Paris
France

Voir sur la carte
PME

L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
Oui
Région
Ile-de-France Ile-de-France Paris
Type d’activité
Organismes privés à but lucratif (à l’exclusion des établissements d’enseignement supérieur ou secondaire)
Liens
Coût total
€ 1 647 873,38

Participants (32)

Partager cette page Partager cette page sur les réseaux sociaux

Télécharger Télécharger le contenu de la page

Dernière mise à jour: 16 Août 2022

Mon livret

Permalink: https://cordis.europa.eu/project/id/634446/fr

European Union, 2025